CRISPR/Cas9-mediated targeted gene correction in amyotrophic lateral sclerosis patient iPSCs
Citations Over TimeTop 10% of 2017 papers
Abstract
Amyotrophic lateral sclerosis (ALS) is a complex neurodegenerative disease with cellular and molecular mechanisms yet to be fully described. Mutations in a number of genes including SOD1 and FUS are associated with familial ALS. Here we report the generation of induced pluripotent stem cells (iPSCs) from fibroblasts of familial ALS patients bearing SOD1 +/A272C and FUS +/G1566A mutations, respectively. We further generated gene corrected ALS iPSCs using CRISPR/Cas9 system. Genome-wide RNA sequencing (RNA-seq) analysis of motor neurons derived from SOD1 +/A272C and corrected iPSCs revealed 899 aberrant transcripts. Our work may shed light on discovery of early biomarkers and pathways dysregulated in ALS, as well as provide a basis for novel therapeutic strategies to treat ALS.
Related Papers
- → Temperature effect on CRISPR-Cas9 mediated genome editing(2017)108 cited
- → Therapeutic applications of CRISPR RNA-guided genome editing(2016)25 cited
- → Elevated expression of exogenous RAD51 enhances the CRISPR/Cas9-mediated genome editing efficiency(2023)10 cited
- → CRISPR/Cas9 system: A promising technology for the treatment of inherited and neoplastic hematological diseases(2018)17 cited
- Progress in the relationship between mutant SOD1 and amyotrophic lateral sclerosis.(2009)